Click image to enlarge
The Human Hypoxia Panel provides assay-specific components for the quantitative determination of EPO and VEGF in serum and plasma.
-
-
Specifications
-
-
Documentation
-
References
Application(s)
|
|
Hypoxia
,
Cardiovascular
|
|
Analyte(s)
|
|
EPO, VEGF-A
|
|
Species
|
|
Human
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
MESO SECTOR S 600MM
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120MM
,
MESO QuickPlex SQ 120
,
MESO SECTOR S 600
|
|
Plate Type
|
|
96-well
|
|
Capture Antibody
|
|
EPO: Mouse Monoclonal VEGF: Goat Polyclonal
|
|
Detection Antibody
|
|
EPO: Mouse Monoclonal VEGF: Mouse Monoclonal
|
|
LLOD (Sensitivity)
|
|
EPO: 2.0 mIU/mL VEGF: 12 pg/mL
|
|
Dynamic Range
|
|
EPO: 2.0-10000 mIU/mL VEGF: 12-100000 pg/mL
|
|
Sample Type
|
|
Serum, Plasma
|
|
Recombinant standards
|
|
EPO: Recombinant protein expressed in CHO cells VEGF: Recombinant protein expressed in insect cells
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
Storage Condition
|
|
Multi-Component
|
|
Product Inserts
|
|
|
Datasheets
|
|
|
SDS
|
|
|
Title
|
Journal
|
Year
|
|
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
|
|
|
|
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial
|
|
|
|
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.
|
|
|
|
Experimental pain and opioid analgesia in volunteers at high risk for obstructive sleep apnea
|
|
|
|
Controlled regulation of erythropoietin by primary cultured renal cells for renal failure induced anemia.
|
|
|
|
View All
|
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters